SLC5A2 and chronic kidney disease: Because the possible mechanisms for the renoprotective effects of SGLT2 inhibitors are assumed to include not only reduction in glomerular hyperfiltration as a result of tubuloglomerular feedback restoration, but also improvement of tubulointerstitial damage [16, 17], improved tubular cell injury may contribute to the greater beneficial effects of SGLT2 inhibitors in participants with type 2 diabetes and CKD with normoalbuminuria.